Oxprenolol

In response to the clinical treatment needs of cardiovascular diseases caused by excessive sympathetic activation, oxprenolol, a classic non-selective β-receptor blocker, can competitively block β1 and β2 adrenergic receptors, slow down the heart rate, reduce myocardial contractility and cardiac output, and simultaneously reduce renin release to inhibit the activation of the RAAS system. It is mainly used clinically for the treatment of hypertension, angina pectoris, sinus tachycardia and arrhythmia. It has clear application value for young and middle-aged hypertensive patients with combined excessive sympathetic tone and people with exertional angina pectoris, and can also be used for the symptomatic control of tachycardia symptoms in hyperthyroidism.

The current overall global market size of non-selective β-receptor blockers is approximately USD 1.2 billion. With its mild antihypertensive effect and low incidence of central adverse reactions, oxprenolol accounts for approximately 3.2% of the segmented market share, and its compound annual growth rate is maintained at around 2.1%. In the domestic market, oxprenolol is still in the mature application stage as a small-variety drug. It has not yet been included in the scope of national centralized volume-based procurement, the number of approved manufacturers is small, the market supply pattern is relatively stable, and the overall price fluctuation range is smaller than that of other similar β-receptor blocker varieties.

The original research enterprise of oxprenolol is Teijin Pharma, and the original research brand name is Trasicor. Its core compound patent expired globally in 1986. The main dosage forms approved for the original research product include tablets, with two specifications of 20mg and 40mg, and the original research product has been included in the FDA Reference Listed Drug Catalog. As of the retrieval time point, there is no A-status registration number for oxprenolol API in China, only a small number of enterprises have submitted registration applications which are under the review process, and oxprenolol tablet products have been approved for marketing in China. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO provides a full set of impurity reference standards for oxprenolol API. Most products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. They fully comply with the compliance requirements of multiple regulations including the Chinese Pharmacopoeia and FDA, and can fully meet the reference standard use needs of pharmaceutical enterprises in the processes of API R&D, quality research and consistency evaluation.